
Metocol5 mg/5 ml
Opsonin Pharma Ltd.
Gastroesophageal Reflux Disease (GERD) Metoclopramide Hydrochloride is an established short-term (up to 12 weeks) treatment for symptomatic GERD in adults who have not responded adequately to other…
Metoclopramide Hydrochloride is an established short-term (up to 12 weeks) treatment for symptomatic GERD in adults who have not responded adequately to other therapy, used to relieve heartburn and related symptoms by increasing gastric emptying and lower esophageal sphincter tone.
Metoclopramide Hydrochloride is FDA-approved for the relief of symptoms associated with acute and recurrent diabetic gastroparesis, including nausea, vomiting, early satiety, bloating, and abdominal pain related to delayed gastric emptying. Because of the risk of tardive dyskinesia, treatment with Metoclopramide Hydrochloride for this indication is generally limited to 12 weeks or less.
Metoclopramide Hydrochloride is an established antiemetic used to prevent and treat nausea and vomiting associated with chemotherapy (often as part of a combination antiemetic regimen for highly or moderately emetogenic chemotherapy), postoperative nausea and vomiting, and other causes of nausea and vomiting when other measures are inadequate.
Metoclopramide Hydrochloride is used, as a single intravenous dose, to stimulate gastric and small bowel motility to facilitate intubation of the small bowel when the tube does not pass the pylorus with conventional maneuvers, and to accelerate gastric emptying and small bowel transit when a barium examination of the stomach or small intestine is delayed.
Metoclopramide Hydrochloride is used off-label by some clinicians to support lactation (as a galactagogue) in mothers with low milk supply; this use is not FDA-approved, is supported only by limited evidence, and carries the same tardive dyskinesia and other risks as approved uses, so it should only be considered under close medical supervision.
The dose of Metoclopramide Hydrochloride depends on the indication being treated, the route of administration, and patient-specific factors such as age, renal function, and body weight, and must be individualized by a qualified healthcare professional. Because of the risk of tardive dyskinesia, treatment with Metoclopramide Hydrochloride should be limited to the lowest effective dose and, for chronic indications such as GERD and diabetic gastroparesis, generally should not exceed 12 weeks unless the treating physician judges that therapeutic benefit clearly outweighs the risk.
Metoclopramide Hydrochloride is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.